Heron Therapeutics, Inc. (HRTX)
After hours:
| Previous close | 2.0800 |
| Open | 2.1100 |
| Bid | 2.2100 x 4000 |
| Ask | 2.2300 x 1200 |
| Day's range | 2.0800 - 2.2200 |
| 52-week range | 2.0500 - 6.3800 |
| Volume | |
| Avg. volume | 1,727,735 |
| Market cap | 259.77M |
| Beta (5Y monthly) | 0.86 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.8600 |
| Earnings date | 23 Mar 2023 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 10.42 |
- PR Newswire
Heron Therapeutics Announces Centers for Medicare & Medicaid Services (CMS) Granted Pass-through Payment Status for APONVIE™, Effective April 1, 2023
Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced that CMS has approved transitional pass-through status for APONVIE (aprepitant) injectable emulsion, which will be established for three years beginning April 1, 2023 under C-code C9145. APONVIE was approved by the U.S. Food and Drug Administration (FDA) for in
- PR Newswire
Heron Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results on Thursday, March 23, 2023
Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced that the company will host a conference call and live webcast on Thursday, March 23, 2023 at 4:30 p.m. ET to report fourth quarter and full year 2022 financial results and discuss recent business highlights.
- PR Newswire
Heron Therapeutics Announces U.S. Commercial Launch of APONVIE™ for the Management of Postoperative Nausea and Vomiting in Adults
Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced APONVIE (aprepitant) injectable emulsion, is now commercially available for intravenous (IV) use in adults for the prevention of PONV.
